PharmetRx® is a novel, computational drug discovery and development platform that uses artificial intelligence to collect and integrate biological, chemical, and human clinical data to discover promising new drug candidates, de-risk product opportunities through pre-clinical studies, and validate drugs in early clinical proof of concept studies.
^Our approach is proven to increase ROI through risk reduction and time and cost savings.
The first drug developed with PharmetRx® was licensed to Supernus (NASDAQ: SUPN) and was granted fast-track approval by the FDA and is currently in a final, Phase III clinical trial.
Driven • Experienced • Focused • Reliable
2102 Business Center Dr
12636 High Bluff Dr #400
Let us know how we can help you
PharmetRx, LLC is a specialty, contract research organization offering a more efficient path to drug discovery, clinical development, and regulatory approval.
Our vision is to be the go-to industry leader for helping pharmaceutical companies avoid disheartening and expensive setbacks related to Phase II clinical trial failures, adverse side effects, or unsuspected toxicities.
In the early days, PharmetRx worked with physician-scientists at the University of Southern California, City of Hope/Beckman Research Institute, University of California Irvine, and the California Institute of Technology, to study the role of genetics and the actions of drugs on human diseases. Initial research efforts focused on correlations between the underlying genetic differences among different patient groups and their differential drug-responses. With the insights that followed, we set to de-convolute the symptoms and uncover the underlying mechanisms of diseases from which these patients suffered. The resulting approach allowed us to then develop novel methods and a comprehensive drug discovery platform, PharmetRx®, to classify diseases, sub-type patient groups, identify key disease pathways, and discover new drugs that were safer and more effective. The first drug developed with PharmetRx® was licensed to Supernus (NASDAQ: SUPN) and was granted fast-track approval by the FDA and is currently in a final, Phase III clinical trial.